Share your videos with the world

Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/

Unfortunately, as Graham is adopted, he doesn\\\'t have an HLA-identical sibling to act as a donor for him. So the Red Cross here in Australia searched the Bone Marrow Registries worldwide for 9 months to find a match. Graham has a rare tissue type and a match was not found. Thanks to generous donations of over $400,000, Graham was able to travel from his home in Melbourne, Australia to Seattle in the USA for a revolutionary, life-saving stem cell treatment in April 2008. On Wed 6th August, he was the 8th person in the world to receive a Stem Cell Transplant using stem cells grown in the lab from an umbilical cord. The treatment was a complete success and he is now leukaemia free. He is back in Melbourne, recovering from the treatment but still has outstanding medical bills of $416,000.